UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
ONCOLOGY

APOGEPHA

Established German pharmaceutical company in urology and oncology

APOGEPHA logo

APOGEPHA

OncologyGermany

Established German pharmaceutical company in urology and oncology

Visit Website

About APOGEPHA

Specialist expertise in urological medicine defines APOGEPHA Arzneimittel GmbH, a German pharmaceutical company that develops and markets a dedicated range of drugs addressing the full spectrum of urological conditions. Operating under the positioning of "Your partner in urology," the company brings together therapeutic products and professional resources for a primarily specialist audience of healthcare professionals and industry partners.

The urological drug portfolio covers a broad clinical range, including treatments and information resources for bedwetting in children, bladder weakness, irritable bladder, cystitis, prostatitis, prostate enlargement, urination disorders, bladder cancer, and prostate cancer. This focused therapeutic breadth reflects a commitment to addressing both benign and oncological conditions within the specialty. The company also addresses oncology-related indications including neutropenia, extending its reach beyond urology into supportive cancer care.

APOGEPHA engages actively with the urological medical community, hosting and supporting professional events such as the Dresden Urology Day, a scientific conference featuring lectures, workshops, and discussion with specialist speakers. A dedicated login area for specialist groups further underlines the company's orientation towards medical professionals rather than general consumers.

The company operates internationally, with its website available in both German and English, and maintains commitments to sustainability and innovation as part of its stated corporate values. Careers and partnerships are also highlighted as active areas of development.

Further information is available at apogepha.de/en/.

Areas of Expertise

Drug DevelopmentOncologyUrology

Services & Capabilities

Drug DevelopmentOncologyUrology
Similar Companies

More in Oncology

A

Adcentrx Therapeutics

Founded in 2021 and headquartered in San Diego, California, Adcentrx Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer and other life-threatening diseases. The company's work centres on its proprietary i-Conjugation platform, which addresses the principal engineering challenges of ADC design, including stable conjugation chemistry, cleavable linker technology, and controlled drug-antibody ratio (DAR 8), to maximise payload delivery to solid tumour cells while limiting systemic toxicity. Clinical Pipeline Adcentrx has advanced two candidates into Phase 1a/b clinical trials. ADRX-0706 is a Nectin-4 ADC currently in Phase 1b evaluation across a range of advanced solid tumours; the US FDA has granted it Fast Track Designation for locally advanced or metastatic squamous cell cervical cancer. ADRX-0405 is a STEAP1-targeting ADC in Phase 1a evaluation for metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer; it carries FDA Orphan Drug Designation for gastric cancer and is regarded as a potential first-in-class candidate for its target. Both programmes build on the i-Conjugation platform's aim to deliver best-in-class or first-in-class ADCs with differentiated clinical profiles. Funding & Partnerships Adcentrx has raised approximately $101 million across three financing rounds, including a Series A+ of $51 million led by Eight Roads Ventures and extended with participation from Quan Capital and Partners Investment. The company has entered a multi-target antibody discovery collaboration with AvantGen to source novel antibody candidates for its ADC pipeline. Further information is available at adcentrx.com.

View profile
A

Astex Pharmaceuticals

Astex Pharmaceuticals applies its proprietary Pyramid Discovery Platform to the identification and development of drug candidates in oncology and central nervous system (CNS) disorders. Operating at the intersection of cutting-edge technology and translational science, the company has assembled research and development teams focused on generating innovative solutions to the complex challenges that characterise both cancer biology and CNS disease. The company has built a broad product portfolio spanning preclinical and clinical stages. Collaboration and licensing agreements with major pharmaceutical companies underpin part of that portfolio, and three partnered products have reached regulatory approval and are now available on the market. This track record of advancing candidates from discovery through to approved medicines reflects the depth of the company's drug discovery capabilities. Oncology and CNS Research Focus Astex's pipeline addresses two of the most challenging and resource-intensive areas of modern medicine. The oncology and CNS drug discovery programmes draw on proprietary technology to identify novel targets and chemical matter, with candidates progressing through preclinical characterisation into clinical evaluation. The organisation also supports early-career scientists through a postdoctoral research programme, reinforcing its commitment to sustaining innovation over the long term. Headquartered in the United Kingdom, Astex operates as a dedicated pharmaceutical research company with a clinical pipeline that continues to expand alongside its partnered development activities. Strategic partnering remains a core element of its business model, enabling the company to advance multiple assets in parallel with major industry collaborators. Further information is available at astx.com.

View profile
R

Roche

Founded in 1896 in Basel, Switzerland, Roche has spent more than a century developing medicines and diagnostic tests that together address some of the most complex conditions in modern healthcare. Listed on the SIX Swiss Exchange and a constituent of the Swiss Market Index, the company is one of the world's largest healthcare businesses by revenue. Operating across two complementary divisions, Pharma and Diagnostics, Roche occupies a distinctive position in the global industry: it is one of very few organisations that integrates therapeutic development with the in-vitro diagnostics capability to inform and monitor those same therapies. Therapeutic Focus Across Major Disease Areas Roche's pharmaceutical pipeline and marketed portfolio span a broad range of therapeutic areas, including oncology, haematology, neurology, ophthalmology, immunology, infectious diseases, inflammatory bowel diseases, cardiometabolic conditions, diabetes, respiratory disease, and women's health. This breadth reflects decades of investment in both internal research and external partnering, reinforced by the 2009 full acquisition of Genentech, which significantly expanded the company's biologics and personalised medicine capabilities. Roche maintains defined ethical standards and a structured innovation process to guide candidate selection and clinical development. Diagnostics as a Strategic Complement The Diagnostics division is widely recognised as the world's largest in-vitro diagnostics business and develops solutions that support clinical decision-making across many of the same disease areas addressed by the Pharma arm. Safety reporting infrastructure and dedicated support for safety officers form part of the diagnostic solutions offering, reinforcing the company's commitment to pharmacovigilance and patient safety throughout the product lifecycle. This integration of drug and diagnostic development is a long-standing strategic pillar at Roche, enabling a personalised healthcare approach that aligns diagnostic insight with therapeutic intervention. Governance at Roche is structured around a Board of Directors, an Executive Committee, and formal board committees, with an Annual General Meeting providing shareholder oversight. The company publishes sustainability goals, ESG performance data, and safety, health and wellbeing metrics as part of its public reporting. Community investment is channelled through the Roche Global Citizenship programme, which covers arts and culture, community disaster relief, humanitarian and social development, and science education initiatives. Further information is available at roche.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy